October 27th 2024
The CRAC channel inhibitor zegocractin significantly improved acute pancreatitis patients' time to eating food and risk of respiratory failure in new data.
October 24th 2024
Test your knowledge of the 2024 American College of Gastroenterology alcohol-associated liver disease guidelines with this clinical quiz!
October 22nd 2024
Test your knowledge of the 2024 American College of Gastroenterology focal liver lesion diagnosis and management guidelines with this clinical quiz!
October 19th 2024
Liver-related mortality in the US increased by nearly 20% from 2018, with lower transplant rates observed in states with the greatest mortality.
October 18th 2024
HCV infection was associated with elevated brachial-ankle pulse wave velocity levels in patients with ESRD receiving hemodialysis.
Hepatology Month in Review: April 2024
The April 2024 month in review features HCPLive’s top coverage of resmetirom, other key hepatic pipeline updates, and recent research about hepatitis C virus.
Addressing Stigma to Improve Outcomes in Alcohol-Related Liver Disease
The second segment of a special report stresses the importance of cross-specialty collaboration with hepatology and psychiatry when treating alcohol-related liver disease.
Recognizing Stigma's Impact on Care for Alcohol-Related Liver Disease
In the first segment of this HCPLive special report, experts discuss the stigma surrounding alcohol use disorder and alcohol-associated liver disease.
Older Age Impacts Health, Birth Outcomes in Hospitalized Pregnant Patients with HCV
Findings highlight an increase in hospitalization among pregnant patients with HCV, further describing age’s impact on mortality, cirrhosis, preterm births, and stillbirths.
Postpartum Hepatitis Flare Risk Increases After Discontinuation of Antiviral Therapy
Tenofovir disoproxil fumarate was safe and effective for preventing mother-to-child transmission of HBV, but discontinuation was linked to postpartum hepatitis flares.
DAA Use Increased After State Medicaid Programs Eased HCV Treatment Restrictions
The modified difference-in-differences analysis found notable increases in DAA use after state Medicaid programs relaxed certain coverage restrictions.
Inequities in HCV Care Cascade Engagement Persist, Even After Introduction of DAA Therapy
Although overall engagement in the HCV care cascade improved after the introduction of DAAs, vulnerable subgroups still received less testing and treatment.
Poorly Controlled Type 1 Diabetes Associated with MASLD in Children, Adolescents
Results showed poorly controlled HbA1C increased the risk of elevated ALT levels in children and adolescents with type 1 diabetes, suggesting an important link to MASLD.
HBV Viral Load, Surface Antigen Positivity Not Independently Associated with NAFLD
HBV DNA and HBsAg were not significantly associated with NAFLD in patients with treatment-naïve HBV, but age, BMI, comorbidities, and certain metabolic laboratory parameters were.
Resmetirom (Rezdiffra) Now Available in US Pharmacies, Marks Turning Point in NASH Management
Madrigal Pharmaceuticals announced resmetirom is available in the US beginning on April 9, 2024, ushering in a new era of NASH management.
Study Debunks Association Between Hepatitis C, Prostate Cancer
An analysis of NHANES data found no significant association between HCV infection and risk of prostate cancer, contrary to findings from previous research.
Facilitated Telemedicine’s Potential for Vulnerable Patient Populations, with Andrew Talal, MD
Talal highlights the use of facilitated telemedicine for increasing access to HCV treatment and other areas it might expand access for underserved patient populations.
Safety, Efficacy of DAAs in Reproductive-Age Women Aid Prevention of Vertical HCV Transmission
Results highlight increased safety and efficacy of curative HCV therapy among reproductive-age female patients compared with males, potentially preventing vertical infection transmission.
WHO Releases New Hepatitis B Guidelines
The 2024 HBV guidelines provide updated evidence-informed recommendations on key priority topics including treatment eligibility, diagnostics, and service delivery.
Increasing Access to HCV Treatment Through Facilitated Telemedicine, with Andrew Talal, MD
Talal discusses the integration of a facilitated telemedicine approach into opioid treatment centers in New York, giving people with opioid use disorder easier access to HCV treatment.
Facilitated Telemedicine Through Opioid Treatment Program Increases HCV Treatment Access
Participants who received facilitated telemedicine initiated DAA therapy faster and had greater cure rates than those who were referred to an off-site hepatitis specialist.
Hepatology Month in Review: March 2024
Our March 2024 hepatology month in review highlights HCPLive’s coverage of the FDA approval of resmetirom for MASH/NASH and other key hepatic pipeline news.
SZN-043 Demonstrates Safety, Pharmacodynamic Effect for Cirrhosis in Phase 1a Trial
SZN-043 showed evidence of target engagement, Wnt signal activation, and effects on liver function, supporting its advancement to a phase 1b trial in severe alcohol-associated hepatitis.
LPCN 1148 Achieves Phase 2 Study Endpoints in Cirrhosis Management
Topline results at week 52 show LPCN 1148 treatment met both the primary and hepatic encephalopathy endpoints in the management of cirrhosis.
Fenofibrates in the Treatment of Primary Biliary Cholangitis
New data suggest adding fibrate therapy to frontline PBC treatment could result in earlier and higher rates of biochemical response.
T Cell Vaccine Demonstrates Safety as Functional Cure for Hepatitis B Virus in Phase 1 Trial
The first-in-human trial of VRON-0200, a novel immunotherapy for chronic hepatitis B virus, presented at the APSAL meeting, demonstrates a promising safety and tolerability profile.
Cirrhosis Complications, Health Care Utilization Linked to Greater Economic Burden
Patients with cirrhosis had greater health care costs than matched controls, attributed mostly to cirrhosis complications and high inpatient utilization in the first year after diagnosis.
Positive Phase 2 Data Shows Benefit of Lanifibranor with Empagliflozin for MASH, T2D
The phase 2, proof-of-concept LEGEND trial achieved its primary efficacy endpoint for absolute reduction in HbA1c at week 24 with lanifibranor alone or in combination with empagliflozin.
Telemedicine at Syringe Access Programs May Address Barriers, Expand Access to HCV Treatment
A recent survey found telemedicine-based HCV treatment at a syringe access program could improve access to treatment among people who inject drugs.
Stephen Harrison, MD: The Role of Weight Loss, Resmetirom in NASH Management
Harrison discusses the role of GLP-1-based therapies in NASH management and situations where resmetirom may be a better option following its recent FDA approval.
Stephen Harrison, MD: FDA Approval of Resmetirom Ends Lengthy Road to First NASH Treatment
Harrison discusses important lessons from obeticholic acid’s FDA failure and what set resmetirom apart from its predecessor, poising it to become the first FDA-approved NASH treatment.
How New Therapies Change Discussions Around Screening, Management of MASH
In the final installment in our 5-part video series, our pair of experts in hepatology touch upon how an approval for MASH would impact conversations around screening for asymptomatic patient populations.
Real-World MASH Populations Compared to MAESTRO-NASH
In part 4 of our 5-part video series, Arab and Banerjee discuss how the study population of MAESTRO-NASH compares to MASH populations in real-world settings.
Understanding Resmetirom's Potential Based on MAESTRO-NASH
In part 3 of our 5-part discussion, Arab and Banerjee dive into the results of the pivotal MAESTRO-NASH trial and how it can inform use of resmetirom in real-world settings.
Challenges, Recommendation Updates in Screening for MASH/MASLD
In part 2 of this 5-part video series, our experts in hepatology discuss the challenges, pitfalls, and recommendations for screening of MASH/MASLD in real-world settings.